Major findings of the current study can be summarized as follows: (i) UA levels were higher in women with pre-gestational overweight/obesity, in the high-risk group (as defined earlier), and in those who required insulin therapy; (ii) UA levels were positively correlated with BMI and glycemia both during pregnancy and postpartum; (iii) gestational age at delivery was negatively correlated with UA levels postpartum; and (iv) the genetic component for UA levels was confirmed for rs1014290, rs12498742, rs734553, and rs16890979 in GLUT9 (encoded by the SLC2A9 gene). This evidence concerns the gene SLC2A9 and obesity disorder.